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The application of novel genetic/genomic technologies to the study of acute leukemia has frequently 
been a proving ground for such approaches in cancer. Recent development of high-resolution single-
nucleotide polymorphism (SNP) arrays allows detailed assessment of the genomes in cancer cells. 
A recent study by Mullighan et al. uses SNP arrays to assess copy number alterations in a large 
group of childhood acute lymphoblastic leukemias and demonstrates frequent mutation of genes 
encoding transcription factors important for B cell development. These studies not only provide 
information about the multistep development of leukemia, but also demonstrate the potential for 
this approach in other cancers.Childhood acute  lymphoblastic  leuke-
mia (ALL)  is the most common malig-
nancy  diagnosed  in  children,  repre-
senting  approximately  one-third  of  all 
pediatric  cancers.  Remarkable  prog-
ress has been made  in  the  treatment 





cured  often  experience  late  effects 
from  chemotherapy,  there  remains  a 





of  leukemia  promises  to  uncover  the 
genetic  lesions  important  for  tumor 
initiation and progression.  Indeed, the 
study of leukemia, perhaps more than 
most  cancers,  has  been  enhanced 
by  the  application  of  newly  devel-
oped tools to study genomic integrity. 
From  early  studies  probing  for  cyto-
genetic  abnormalities  to  more  recent 
gene  expression  studies,  leukemia  is 
frequently  a  cancer  where  new  tech-
nologies yield  important  insight. Such 
studies have led to the identification of 
a  number  of  recurrent  translocations 
and  other  genetic  alterations  that  are 
currently  used  to  risk  stratify  patients 
based on their likelihood of being cured 
with standard therapy. Hopefully, in the 308  Cancer Cell 11, April 2007 ©2007 ElFigure 1. SNP Analysis of B-ALL Identi-
fies Recurrent Mutations in Genes Im-
portant for Normal B Cell Development
Mullighan  et  al.  analyzed  242  pediatric  ALL 
cases using genome-wide SNP analysis. Re-
current deletions in B-precursor ALL samples 
were  identified  in  genes  such  as  EBF1  and 
PAX5  that are known regulators of B cell de-
velopment. This suggests that perturbation of 
normal  pathways  that  promote  development 
from common  lymphoid progenitors  (CLP)  to 
pre-B cells  is an important part of the patho-
genesis of B-ALL and highlights the power of 
genome-wide assessment of cancer cells.sevier Inc.not  too  distant  future,  these  genetic 




A  recent  study  by  Mullighan  et  al. 
has  taken  an  important  next  step  in 






in  cancer  cells.  This  study  assesses 
leukemia cell DNA obtained  from 242 
pediatric  patients  with  ALL  through 
the  use  of  single-nucleotide  polymor-





alterations  per  ALL  sample,  demon-
strating  a  remarkably  stable  genome 







MLL  gene  on  chromosome  11q23,  to 
6.8  alterations  per  genome  in  cases 
with BCR-ABL translocations, perhaps 
providing  insight  into  the  number  of 
genetic  alterations  necessary  for  leu-
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for  recurrent  alterations,  54  recurrent 









cases)  play  important  roles  in  normal 
B cell  development,  thus  immediately 
highlighting  a  potential  role  for  these 
genes in the pathophysiology of B-pre-
cursor ALL (B-ALL) (Figure 1).
Further  characterization  of  the 
mutations in genes associated with B 
cell development supports the impor-




informative  case,  two  populations 
of  leukemic  blasts  were  identified, 
a  relatively  immature  CD10/CD22dim 
population and a more mature CD10/
CD22bright  population.  FISH  analy-
sis  of  flow-sorted  blasts  revealed 
homozygous deletions of EBF1 in the 





in  the  absence of EBF1,  are  strongly 
supportive of EBF1 mutations playing 
a  role  in  the perturbed  lymphoid dif-
ferentiation  found  in  B-ALL  (Lin  and 
Grosschedl, 1995).
Moreover,  the  study  showed  that 
PAX5 is frequently the target of genetic 
alterations in B-ALL. The most frequent 
types  of  alteration  identified  by  SNP 
analysis were monoallelic deletions of 
varying  size  that  primarily  resulted  in 
loss of  function. Further characteriza-
tion of  the PAX5 gene  in other B-ALL 
cases  identified  a  PAX5-ETV6  trans-








provide normal transcriptional activity. Functional  studies  demonstrated  the 
fusion  proteins  competitively  inhibit 
the  transcriptional  activation  activity 
of  wild-type  PAX5,  thus  supporting  a 
dominant-negative  role  for  the  fusion 











The  study  also  identified  deletions 
involving  additional  genes  encod-
ing  regulators of B cell development, 
including  IKZF3(AIOLOS),  LEF1,  and 
TCF3(E2A).  Differences  in  the  fre-
quency  and  type  of  mutations  were 
observed  among  various  subtypes 




high  frequency  of  PAX5  monoallelic 
deletions  (28%) were found  in B-ALL 
cases with TEL-AML1 rearrangement. 
It  will  be  of  interest  to  determine  if 
there is a statistically significant asso-




alterations  cooperate  with  chromo-
somal  translocations  such  as  BCR-
ABL,  MLL-translocations,  or  TEL-
AML1  during  leukemia  progression. 
It  is  widely  believed  that  previously 
defined  chromosomal  translocations 
are  initiating events  in childhood ALL 
(Greaves  and  Wiemels,  2003).  How-
ever,  detailed  epidemiologic  stud-
ies and sophisticated murine models 
suggest  that  multiple  genetic  events 
are  necessary  for  ALL  development, 
as  has  been  similarly  hypothesized 
in  acute myelogenous  leukemia  (Gil-
liland and Griffin, 2002; Greaves and 












development,  it  appears  that  pertur-







newly  defined  genetic  abnormalities 
can  be  used  as  prognostic markers, 
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